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Abstract
Background Molecular markers and the rich biological
information they contain have great potential for cancer
diagnosis, prognostication and therapy prediction. So far,
however, they have not superseded routine histopathology and
staging criteria, partly because the few studies performed on
molecular subtyping have had little validation and limited clinical
characterization.
Methods We obtained gene expression and clinical data for
412 breast cancers obtained from population-based cohorts of
patients from Stockholm and Uppsala, Sweden. Using the
intrinsic set of approximately 500 genes derived in the Norway/
Stanford breast cancer data, we validated the existence of five
molecular subtypes – basal-like, ERBB2, luminal A/B and
normal-like – and characterized these subtypes extensively with
the use of conventional clinical variables.
Results We found an overall 77.5% concordance between the
centroid prediction of the Swedish cohort by using the Norway/
Stanford signature and the k-means clustering performed
internally within the Swedish cohort. The highest rate of
discordant assignments occurred between the luminal A and
luminal B subtypes and between the luminal B and ERBB2
subtypes. The subtypes varied significantly in terms of grade (p
< 0.001), p53 mutation (p < 0.001) and genomic instability (p =
0.01), but surprisingly there was little difference in lymph-node
metastasis (p = 0.31). Furthermore, current users of hormone-
replacement therapy were strikingly over-represented in the
normal-like subgroup (p  < 0.001). Separate analyses of the
patients who received endocrine therapy and those who did not
receive any adjuvant therapy supported the previous hypothesis
that the basal-like subtype responded to adjuvant treatment,
whereas the ERBB2 and luminal B subtypes were poor
responders.
Conclusion We found that the intrinsic molecular subtypes of
breast cancer are broadly present in a diverse collection of
patients from a population-based cohort in Sweden. The
intrinsic gene set, originally selected to reveal stable tumor
characteristics, was shown to have a strong correlation with
progression-related properties such as grade, p53 mutation and
genomic instability.
Introduction
A significant reduction of disease burden from breast cancer
can be achieved by a better characterization of its potentially
fatal forms. Spread of the disease, cell structure, differentiation
and growth patterns have been used to classify tumors and to
make a clinically relevant assessment of their metastatic
potential. With an increasing use of screening programs, more
early-stage tumors are diagnosed, creating a need for new
tools for prognostication and therapy prediction. Standard
clinical factors often lead to undertreatment and overtreatment
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of large patient cohorts. The classical factors also offer little or
no insight into the pathogenesis and biological separation of
distinct subtypes of human breast cancers.
The emergence of powerful molecular techniques allowing
genome-wide analysis has the potential to improve tumor clas-
sification markedly. Using microarray-based gene expression
analyses, Sorlie and colleagues [1] described five subtypes of
breast cancer, roughly dividing estrogen receptor (ER)-nega-
tive and ER-positive tumors into two and three subclasses,
respectively. Molecular techniques are growing more and
more important as diagnostic and prognostic tools, but they
have not yet come into routine clinical practice. One reason
could be there had been limited validation [2] as well as limited
clinical description [1] of the molecular subtypes. Validation is
often difficult in this context, because results are influenced
not only by patient selection but also by the choice of methods
used to analyze gene expression data.
Consequently, our aims for this study were, first, to validate the
previously derived molecular subtypes on a large population-
based cohort of 412 patients in Sweden, and second, to char-
acterize the genetic subtypes with the use of routine clinical
variables, and to achieve these goals by using transparent and
widely accepted analysis methods.
Materials and methods
The total study population consisted of 412 patients for whom
we had quality-controlled RNA expression microarray data,
including 159 patients from Stockholm and 253 from Uppsala.
The Stockholm subcohort includes all breast cancer patients
that were operated at the Karolinska Hospital from 1 January
1994 to 31 December 1996 identified from the population-
based Stockholm–Gotland breast cancer registry established
in 1976. The ethical committee at the Karolinska University
Hospital approved this microarray expression project. This
cohort has previously been described in detail [3,4].
Study population
The Stockholm–Gotland Breast Cancer Registry, supple-
mented with patient records, were examined for information on
tumor size, number of retrieved and metastatic axillary lymph
nodes, hormonal receptor status, distant metastases, site and
date of relapse, initial therapy, therapy for possible recur-
rences, and date and cause of death. Tamoxifen and/or goser-
elin were normally used for hormonal treatment, whereas
mostly six courses of intravenous cyclophosphamide–meth-
otrexate–5-fluorouracil (CMF) on days 1 and 8 were used as
adjuvant chemotherapy, except for high-risk patients. After pri-
mary therapy, patients were recommended to have regular
clinical examinations and yearly mammograms, in addition to
laboratory and X-ray tests guided by clinical signs and symp-
toms. Patients followed-up outside the Karolinska Hospital
were tracked by using their unique Swedish personal identifi-
cation number. There was no loss to follow-up.
Relapse site, date of relapse, relapse therapy, and date of
death were ascertained until May 2002. The average follow-up
was 6.1 years. Cause of death was coded as death due to
breast cancer (including those with distant metastases, but
dying from other causes), death due to other malignancies,
and death due to non-malignant disorders. Subsequent pri-
mary malignancies were identified through the population-
based Swedish Cancer Registry.
A second data source (referred to as Uppsala subcohort) con-
sists of a population-based cohort of primary breast cancer
patients receiving primary therapy from 1987 to 1989 in the
county of Uppsala, Sweden. From the initial set of 315
patients, representing 65% of all breast cancer patients in the
Uppsala county during these years, we were able to obtain
quality-controlled RNA expression profiles from 253 frozen
tumors. The patients were followed until December 1999.
Overall, 76 lymph-node-positive and 26 lymph-node-negative
patients received adjuvant therapy, mostly intravenous CMF-
based therapy or adjuvant tamoxifen, whereas 130 patients
did not receive adjuvant therapy. The ethical committee at the
Karolinska Institutet approved this RNA expression study, and
consent was obtained from each patient for the use of the bio-
logical tissues.
RNA preparation
RNA was prepared with an RNeasy spin column kit (Qiagen,
Valencia, CA, USA). Frozen tumors were cut into minute
pieces and homogenized for 40 seconds in RNeasy lysis
buffer. Proteinase K was added [5] and the samples were
incubated for 10 minutes at 55°C, followed by centrifugation
and the addition of ethanol. After the transfer into RNeasy col-
umns, DNase was added to increase RNA quality. RNA quality
was assessed with an Agilent 2100 bioanalyzer (Agilent Tech-
nologies, Rockville, MD, USA). The material was stored at -
70°C. The amount of RNA for each probe preparation varied
between 2 and 5 µg. First-strand cDNA synthesis was gener-
ated by using a T7-linked oligo(dT) primer, followed by sec-
ond-strand synthesis. The in vitro transcription reactions were
performed in batches to generate biotinylated cRNA targets,
which were subsequently chemically fragmented at 95°C for
35 minutes.
Fragmented, biotinylated cRNA (10 µg) was hybridized at
45°C for 16 hours to Affymetrix high-density oligonucleotide
HG-U133AB gene-chip arrays. The arrays were then washed
and stained with streptavidin–phycoerythrin (10 µg/ml). Signal
amplification was achieved with a biotinylated anti-streptavidin
antibody. The scanned images were inspected for the pres-
ence of artifacts. In case of defects, the hybridization proce-
dure was repeated. Expression values and detection calls
were computed from raw data by following the procedures
outlined for the Affymetrix MAS 5.0 analysis software [6]. Glo-
bal mean normalization of MAS 5.0 expression was performedAvailable online http://breast-cancer-research.com/content/8/4/R34
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on a logarithmic scale to reduce differences in chip intensity
[7].
A sample was either relabeled and the hybridization repeated,
or excluded from further analysis if a scaling factor greater than
four was necessary, if less than 30% present calls were found,
or if the squared multiple correlation coefficient of the expres-
sion data on the array to all other arrays was below 0.6.
Microarray data analysis and clustering methods
A publicly available set of 122 tumor samples [2] was down-
loaded from the Stanford Microarray Database [8]. Mean-nor-
malized log2 ratios of expression values were used in the
analysis. The so-called 'intrinsic' gene list as described by Sor-
lie and colleagues [2] was used to select genes of interest.
CloneID and Unigene ID were matched by using the Stanford
SOURCE Search website [9]. A total of 516 genes out of the
original 552 had valid Unigene IDs. We excluded 32 genes
assigned to multiple Unigene clusters and based our analyses
on the resulting 484 genes with unique Unigene IDs.
Gene expression data from HG-U133AB Affymetrix chips
were available for the Swedish samples. Matching between
the Norway/Stanford data and the two Swedish data sets was
achieved by using Unigene IDs build 181. In all, there were
465 genes with unique Unigene IDs that matched the Stan-
ford intrinsic gene set.
Genes were median-centered and subtypes were defined by
a hierarchical clustering of the Norway/Stanford data, using
uncentered correlation as a distance metric and an average-
linkage clustering algorithm. This step attempts only to repro-
duce the results of Sorlie and colleagues [2], so we expect to
find their five subtypes (basal-like, ERBB2, luminal A, luminal
B and normal-like). The profile of a subtype – the so-called
'centroid' – was computed by averaging expression values
across each gene within each of the subtypes. Thus, the cen-
troid simply represents the average gene expression over the
tumors in a subtype. To obtain better defined and more homo-
geneous genetic profiles, we used only representative tumor
samples in defining the centroids; representative was defined
as having Pearson correlation of at least 0.2 with all other sam-
ples in the same subtype class.
Consistency of clustering results
We then assigned the Swedish tumor samples to the five sub-
types discovered in the Norway/Stanford data. This was
achieved by calculating the Pearson correlation between each
sample and each of the five centroids. Samples were then
assigned to the subtype of the centroid with the largest corre-
lation coefficient; we will refer to this procedure as 'centroid
prediction'. If the correlations with all five centroids were
below 0.1, a sample was labeled as 'unclassified'.
The centroid prediction of tumor samples to specific subtypes
as described above represents a classification procedure,
using Norway/Stanford data as the training set; that is, we
forced the samples to fit into one of five prespecified catego-
ries. We evaluated whether this class allocation was consist-
ent with the k-means clustering of the samples themselves. If
there had been little consistency between the centroid predic-
tion and the k-means clustering, then the class assignment
would have been spurious. In this analysis we excluded the
unclassified samples.
In brief, samples were scaled to have a mean of 0 and a stand-
ard deviation of 1, and clustered with a k-means algorithm with
the number of cluster centers set to k = 5. The resulting five
clusters were matched to the centroid-predicted labeling in
such a manner as to maximize their agreement. The scaling
step was included to make the Euclidean distances used in
the  k-means algorithm more similar to the correlation dis-
tances used in the centroid prediction. To allow for potential
systematic differences in sample handling, the Stockholm and
Uppsala cohorts were clustered separately. Concordance is
expressed as the overall percentage of samples classified in
the same group by the centroid prediction and k-means clus-
tering methods. Intuitively, if this procedure is applied to ran-
domly generated data, there will be little concordance
between the two methods. Any discordant assignment indi-
cates some similarity or overlapping characteristics between
two subtypes.
Clinical and survival data analysis
The genetically derived subtypes were characterized on a
number of clinical characteristics, including age at diagnosis,
tumor size, lymph-node status, grade and receptor status, and
use of hormone replacement therapy (HRT). Mutation of p53
was ascertained by complete sequencing of the p53 gene
[10]. Genomic instability was assessed on the basis of image
cytometric data of DNA content; tumors were classified into
diploid, aneuploid or tetraploid groups, and also whether they
were genomically stable or unstable according the stemline-
scatter index (SSI) developed by Kronenwett and colleagues
[11]. SSI is the sum of the percentages of cells with DNA con-
tent values in the S-phase region (S phase), plus the percent-
age of cells with DNA content values exceeding twice the
modal value plus 1c (G2 exceeding rate, or G2 Exc), plus the
coefficient of variation of the tumor stemline. A genomically
unstable tumor is defined to have an SSI of more than 8.8, indi-
cating a significant cell-to-cell variation in DNA content.
Finally we performed a survival analysis, considering as out-
come both the relapse-free interval and the occurrence of
death due to either breast cancer or distant metastases. Given
their uncertain biological interpretation, 43 unclassified sam-
ples (n  = 20 in Stockholm and n  = 23 in Uppsala) were
excluded from the analysis. To obtain homogeneously defined
treatment groups, we also excluded from the StockholmBreast Cancer Research    Vol 8 No 4    Calza et al.
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cohort any patients with no adjuvant therapy and those treated
with chemotherapy. In Stockholm, post-operative adjuvant
therapy was a standard procedure; patients who did not
receive the therapy either denied it or were considered too
unfit for treatment. In contrast, the adjuvant-untreated patients
in Uppsala were part of a clinical trial. We analyzed separately
the endocrine-treated patients (n = 171) and those who did
not receive any adjuvant therapy (n = 130). Among the endo-
crine-treated patients there were 16 patients who also
received chemotherapy. To maintain power, these were kept in
the analysis. Univariate Cox proportional models considered
as a unique predictor variable the tumor subtype. All of the sta-
tistical analysis was performed with R [12] and Bioconductor
[13], whereas clusters were displayed with treeview [14].
Results
Norway/Stanford data
We first analyzed the Norway/Stanford data to establish the
previous molecular subtypes: basal-like, ERBB2, luminal A,
luminal B and normal-like. This was achieved by hierarchical
clustering of the 122 samples from Norway/Stanford based on
516 genes (Figure 1S in Additional file 1). The five subgroups
reported by Sorlie and colleagues [2] were identifiable, and
93% of the tumors clustered in the same way. Moreover, the
clusters were characterized by the same main genes as previ-
ously described, including ERBB2, GRB7 and PPARBP for
the ERBB2 cluster, CXCL1, KRT5, KRT17 and TRIM29 for
the basal-like cluster, ESR1, GATA3 and SCUBE2 XBP1 for
luminal A, SQLE, GGH and LAPTM48B for luminal B, and
PIK3R1 and AKR1C1 for normal-like samples (Figure 2S in
Additional file 1).
Subtype centroids were then defined by including tumors with
a pairwise correlation higher than 0.2, as shown in Table 1. All
the samples considered in the centroids were also part of the
centroids defined by Sorlie and colleagues [2], except for the
ERBB2 centroid, where three samples out of seven were
unclassified by Sorlie and colleagues [2]. The centroids are
marked in a dendrogram in Figure 1S in Additional file 1.
Swedish data
Using centroid prediction towards the five subtypes in the Nor-
way/Stanford data, 59 samples were classified as basal-like,
43 as ERBB2, 122 as luminal A, 54 as luminal B and 91 as
normal-like tumors (Table 1). A total of 43 samples showed a
correlation of less than 0.1 with any centroid and were conse-
quently put into the unclassified group.
The data were then clustered by using the same hierarchical
clustering procedure as for the Norway/Stanford data; the
dendrograms are displayed in Figures 3S and 4S in Additional
file 1. As reported previously [15,16], the main separation was
between tumors overexpressing estrogen-related genes, pre-
viously labeled as normal-like and luminal A/B, versus tumors
negative for these genes, including the basal-like and ERBB2
subtypes. However, in contrast with the Norway/Stanford and
Stockholm data, almost all Uppsala samples classified as lumi-
nal B (28 of 31) clustered in the same main branch as basal-
like and ERBB2 clusters, whereas normal-like tumors were
located close to the luminal A group.
Table 1
Norway/Stanford centroid size (N), minimum subtype 
correlation (R) and centroid-prediction assignments
Subtype Norway/Stanford Sweden
NRNPercentage
Basal-like 17 0.37 59 14.3
ERBB2 7 0.23 43 10.4
Luminal A 9 0.27 122 29.6
Luminal B 7 0.20 54 13.1
Normal-like 7 0.35 91 22.1
Unclassifie
d
- - 43 10.4
Samples with a Pearson correlation of less than 0.1 were labeled as 
unclassified.
Table 2
Concordance between centroid-prediction classification (rows) and k-means clustering label assignment (columns) for the Swedish 
cohort
Subtype Basal-like ERBB2 Luminal A Luminal B Normal-like Total
Basal-like 46 12 0 0 1 59
ERBB2 0 39 0 1 3 43
Luminal A 0 1 87 34 0 122
L u m i n a l  B 02 103 215 4
N o r m a l - l i k e 2052 8 2 9 1
T o t a l 4 87 39 26 98 7 3 6 9Available online http://breast-cancer-research.com/content/8/4/R34
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Most samples associated with the basal-like subtype clus-
tered together, showing a distinctive genetic profile, charac-
terized by the overexpression of KRT  genes and TRIM29,
among others. Other subtypes were also characterized by the
corresponding genes found in the Norway/Stanford data (Fig-
ure 5S and 6S in Additional file 1). Consistent with previous
findings is the observation that the basal-like cluster is the
most homogeneous in both Swedish cohorts, with a high cor-
relation among samples and a clear separation from other sub-
types.
Consistency of clustering result
In the Swedish cohort, the overall concordance rate between
the centroid prediction and the k-means clustering was 77.5%
(Table 2), comparable to the 74.6% concordance rate
observed for the Norway/Stanford data (data not shown). The
highest rate of discordant assignments occurred between the
luminal A and luminal B subtypes, and between the luminal B
and ERBB2 subtypes. Thirty-four (9%) tumors were classified
as luminal A by the centroid prediction but clustered as luminal
B in the k-means clustering. A total of 21 (6%) tumors were
classified as luminal B by the centroid prediction but clustered
as ERBB2 in the k-means clustering. Twelve tumors had dis-
cordant assignments to the basal and ERBB2 subtypes. The
normal-like subtype had the fewest discordant assignments.
To understand the reasons for discordant assignments, we
investigated the expression of the distinguishing genes of
each subtypes. The 21 luminal B tumors clustered to ERBB2
had relatively high expression of the ERBB2 and GRB7 genes
and low expression of ESR1  gene, all characterizing the
ERBB2 subtype. The 34 luminal A tumors clustered to luminal
B displayed a high expression of GGH and SQLE, but low
expression of SCUBE2, NAT1 and LTF [17]. In comparison
with those consistently classified as basal-like (n = 46), the
tumors clustered as ERBB2 (n = 12) showed a lower average
expression in KRT17, KRT5 and especially GABRP, which
has been reported to be associated with ER-/HER2- breast
cancers [18].
Tumor subtypes and estrogen receptor status
Breast cancer subtype classification is closely related to ER
status, with a high proportion of luminal A/B and normal-like
tumors having ER-positive protein overexpression, whereas
basal-like and ERBB2 tumors have a higher proportion of ER
negativity [15,16,19]. These findings were confirmed in the
Swedish data (Table 3). However, a large discrepancy was
seen in the proportion of ER-positive tumors between the
basal-like (45.8%) and ERBB2 (67.4%) groups. This discrep-
ancy is surprising because we did not see any obvious differ-
ence in the expression of the ESR1 gene (Figure 1). For the
luminal A/B and normal-like subtypes, the expression of the
ESR1 gene seems consistent with the protein expression.
Tumor subtypes and clinical characteristics
When the molecular subtypes were characterized according
to tumor characteristics, treatment and HRT use, quite a com-
plex pattern emerged (Table 4). The youngest women were
found in the basal-like group, in which 27.5% were premeno-
pausal. The average tumor size and the proportion of tumors
smaller than 21 mm were not dramatically different among the
groups, with the exception of the ERBB2 group, in which the
tumor size tended to be larger. Basal-like tumors tended to
have high Elston grade and to be genomically unstable, but
surprisingly there was no significant difference in lymph-node
metastasis status between the different subtypes. A majority
(65%) of basal-like tumors had p53-sequence mutations and
a relatively high 40% of the patients were current or former
users of HRT.
The ERBB2 group consisted of elderly women with large
tumors, of which 57% were Elston grade III, 39% had a p53
mutation and 71% were genomically unstable aneuploids, an
even higher percentage than in the basal-like subtype. At the
same time these patients were 67% ER-positive and 72% pro-
gesterone receptor-positive. The luminal B group revealed the
same complex pattern as ERBB2 but on a less aggressive
scale, particularly with a smaller proportion of unstable aneu-
ploid tumors. Tumor size and receptor status indicated a low
metastatic potential, yet 55% had an Elston grade of III.
Found mostly in postmenopausal women, the luminal A and
normal-like tumors tended to be small and receptor positive,
were unlikely to be Elston grade III, tended to have wild-type
p53 status and tended to be genomically more stable. One
striking difference between these two subtypes was in the
ongoing use of HRT: 51% in the normal-like group versus 5%
in luminal A.
Table 3
Estrogen receptor (ER) status by tumor subtype in the Swedish cohort
ER status Basal-like ERBB2 Luminal A Luminal B Normal-like
E R - n e g a t i v e 3 2 1 4 377
ER-positive 27 29 115 47 84
ER-positive (%) 45.8 67.4 97.5 87.0 92.3Breast Cancer Research    Vol 8 No 4    Calza et al.
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Tumor subtypes and prognosis
Genetically derived subtypes seem to be distinct biological
entities, so we expect them to have prognostic implications.
Overexpression of the ERBB2 gene has been associated with
poor clinical outcome, whereas there is some indication of
poor prognosis for tumors overexpressing citokeratin 17 and
5, characteristics of the basal-like subtype [16,20,21]. Previ-
ous findings [15] suggest that prognostic discrepancies
between subtypes reflect different responses to therapy,
especially endocrine therapies. To gain a better insight we per-
formed separate analyses for patients with endocrine therapy
and for those without any adjuvant treatment. However, inter-
pretation is still rather limited as a result of the small number of
patients.
Regardless of whether or not the patient received adjuvant
therapy, the ERBB2 group had the worst recurrence-free sur-
vival, whereas the luminal A and normal-like groups had the
best prognosis (Figure 2). Among endocrine-treated patients,
the luminal B subtypes had a significantly lower survival than
the luminal A and normal-like tumor groups, and the patients in
the basal-like group did not differ significantly from those in the
luminal A group. Among the untreated patients, however, the
basal-like group had a survival pattern more similar to the lumi-
nal-B and ERBB2 patients. Similar results were obtained for
breast cancer-specific survival (Figure 7S in Additional file 1).
Discussion
We were able to confirm that the intrinsic signature described
previously [1] exists in a broad population-based cohort of
breast cancers. This is by far the largest validation and clinical
characterization of the molecular subtypes to date. Previous
characterization was given in [1] – p53 mutation status on 69
cases – and in an unpublished report [22], reviewed in [23].
The different prognosis of the subtypes was already reflected
in the tumor characteristics, although the patterns were com-
plex. By performing a separate analysis of endocrine-treated
and adjuvant-untreated patients we were also able to evaluate
the differences between subtypes in terms of both prognosis
and response to therapy.
Normal-like tumors were small, found in postmenopausal
women, seldom of Elston grade III, mostly stable diploid and
more prevalent among HRT users. They had a favorable prog-
nosis under endocrine therapy. Luminal-A tumors closely
resembled normal-like tumors but were not associated with
HRT use and had a superior prognosis regardless of adjuvant
therapy. In contrast, the ERBB2 tumors showed a 50%
relapse-free 5-year survival not influenced by therapy. The
poor prognosis was reflected in large tumor size, high propor-
Figure 1
Logarithmic expression of the ESR1 gene Logarithmic expression of the ESR1 gene. Boxplots are shown of 
ESR1 gene expression values (log2 transformed) against subtype in 
both Swedish cohorts.
Figure 2
Kaplan-Meier relapse-free survival curves Kaplan-Meier relapse-free survival curves. Survival curves are shown for 
the tumor subtypes in (a) patients with endocrine therapy and (b) 
patients without any adjuvant therapy. The p value, computed with Cox 
regression, is for simultaneous comparison of all the curves.Available online http://breast-cancer-research.com/content/8/4/R34
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Table 4
Descriptive statistics by tumor subtypes in the Swedish cohort
Characteristic Basal-like ERBB2 Luminal A Luminal B Normal-like p
n = 59 n = 43 n = 122 n = 54 n = 91
Cohort (n) 0.51e
S t o c k h o l m 2 51 53 92 33 7
U p p s a l a 3 42 88 33 15 4
Mean age at breast cancer diagnosis 54 59 66 61 59 <0.001e
Menopausal status (%) 0.0807e
Premenopausal 27.5 13.3 10.9 24.4 18.6
Postmenopausal 72.5 86.7 89.1 75.6 78.6
Mean tumor size (mm) 22.9 27.9 21.8 22.6 20.7 0.0345f
Tumor size < 21 mm (%) 51 35 57 42 70 <0.001e
Elston grade <0.001e
I 3.5 4.8 34.5 5.7 43.2
II 21.1 38.1 54.3 39.6 52.3
III 75.4 57.1 11.2 54.7 4.5
p53 mutation (%)a 64.7 39.3 9.6 38.7 3.7 <0.001e
HRT (%)b <0.001e
Never 60.0 78.6 81.6 82.6 48.6
Former 8.0 7.1 13.2 8.7 0.0
Ongoing 32.0 14.3 5.3 8.7 51.4
Lymph-positive (%) 29 48 33 41 33 0.312e
Estrogen receptor positive (%) 45.8 67.4 97.5 87.0 92.3 <0.001e
Progesterone receptor positive (%) 54.2 72.1 93.2 77.8 92.3 <0.001e
Genomically unstable (%)b 76.0 78.6 56.4 78.3 37.1 0.0031e
Genomic instability by ploidyb 0.0123e
Diploid stable 12.0 7.1 25.6 4.3 40.0
Diploid unstable 4.0 0.0 20.5 26.1 17.1
Tetraploid stable 4.0 7.1 7.7 8.7 8.6
Tetraploid unstable 16.0 7.1 12.8 13.0 0.0
Aneuploid stable 8.0 7.1 10.3 8.7 14.3
Aneuploid unstable 56.0 71.4 23.1 39.1 20.0
Treatment type (%)c 0.0353e
None 39.7 35.7 43.3 35.8 46.2
Endocrine 36.2 45.2 50.8 56.6 44.0
Chemotherapy 15.5 16.7 5.0 5.7 7.7
Radiotherapy 8.6 2.4 0.8 1.9 2.2
Breast cancer event within 5 years (%)d 30 51 17 43 19 <0.001e
ap53 data were available only for the Uppsala cohort. bHRT and genomic instability were available only for the Stockholm cohort. cFor the Stockholm 
cohort, endocrine comprises endocrine treatment alone and with any other combination. Chemotherapy refers to chemotherapy alone or associated 
with radiotherapy. Radiotherapy means radiotherapy alone. dBreast cancer event refers to relapse or death for breast cancer. ePearson χ2 test. 
fAnalysis of variance test.Breast Cancer Research    Vol 8 No 4    Calza et al.
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tion of Elston grade III and unstable aneuploids, and few ER-
positive tumors. Luminal B tumors had a clearly worse progno-
sis than luminal A ones, and were apparently less responsive
to the hormonal therapy than the basal-like and normal-like
tumors [2]. In comparison with the luminal A group, this group
had a higher proportion of Elston grade III, p53 mutation and
lymph-node positive tumours, confirming the hypothesis of a
more proliferative profile [23]. Surprisingly, although the basal-
like tumors had even fewer ER-positive tumors and more high-
grade tumors, they had better relapse-free survival than the
ERBB2 tumors, especially among the endocrine-treated
patients. It is worth noting that about one-third of the patients
with basal-like tumors used HRT at the time of diagnosis.
The intrinsic signature set of approximately 500 genes was
originally selected on the basis of their stable expression
between pairs of samples taken from the same tumors, before
therapy and after 15 weeks of neoadjuvant therapy [1]. This
implies that the set is enriched in genes whose expression pat-
terns are characteristic for individual tumors as opposed to
those that vary as a function of tissue sampling, and hence
would be ideally suited for classification. Another recent study
[24] showed that the subtypes were also observed among
Asian-Chinese patients, although this study performed only
the hierarchical clustering and identified only three subtypes.
The discordant subtyping between the centroid prediction and
k-means clustering indicates some overlapping characteristics
between subtypes, and potentially reveals a biological hetero-
geneity more complex than the subtypes alone. Discordances
occurred most frequently between the luminal A and luminal B
groups and between the luminal B and ERBB2 groups. Not
surprisingly, despite differences in receptor status, luminal B
and ERBB2 share similar clinical – such as tumor grade – and
prognostic characteristics. This suggests that there must in
fact be grade-associated and outcome-associated genes in
the intrinsic gene set, and that these two subtypes have similar
expression in these genes. A similar argument can also be
made from the large confusion of luminal A and luminal B,
namely that this must have been driven by ER-associated
genes, because these two subtypes have similar receptor
characteristics. Having the fewest discordances, the normal-
like subtype seemed to have the most distinctive profile. One
of the most striking characteristics was the high proportion of
HRT users within this subtype.
Although the intrinsic signature is expected to reveal funda-
mental tissue properties, such as origin (basal-like versus lumi-
nal), our study supports the hypothesis that the subtypes are
distinct biological entities with distinct clinical characteristics.
Our study showed how they differed in progression-related
characteristics, such as tumor grade, p53  mutation and
genomic instability. This means that there must be a strong
correlation between the intrinsic gene set and other progres-
sion-related signatures based on p53 transcription profile [4],
proliferation or genomic instability, and possibly an inherent
capability to metastasize [25]. The extent to which the different
signatures contribute independent information toward clinical
progression or prognosis requires further study.
Our findings further support the hypothesis of a reduced
response to hormone-based treatments for ERBB2 and lumi-
nal B tumors [23]. Whereas luminal A tumors seem to have a
good prognosis overall, luminal B tumors had a poor prognosis
regardless of endocrine therapy, indicating some resistance to
therapy. This may be explained at least partly by a worse clini-
cal profile, with a higher tumor grading and a higher proportion
of p53 mutation. In contrast, in the endocrine-treated group
the basal-like subtype seemed to survive better than expected
considering its poor clinical characteristics including its high
proportion of Elston grade III (75%) and few ER-positive
(46%) tumors. The ERBB2 tumors had the lowest relapse-free
survival: approximately 50% of the patients had either died
from breast cancer or experienced distant metastases. Over-
expression of the human transmembrane tyrosine kinase
growth factor receptor (HER-2), characteristic of the ERBB2
group, has been associated with more aggressive forms of
tumor and with resistance to endocrine therapies [26-28].
Conclusion
One strength of our study was that we were able to analyze
hormone-adjuvant-treated and untreated patients separately.
Thus, it seems that the molecular subtypes also carry therapy
predictive information. However, when interpreting the results
it should be emphasized that observational studies are not
optimal for evaluating therapy. Reverse causality, in which a
patient with a more aggressive tumor is more likely to receive
therapy, is a major problem, producing an apparent result that
therapy worsens survival. Ideally, to establish microarray-
based predictive markers we would use a randomized compar-
ison of adjuvant therapy versus placebo, but we are not cur-
rently aware of any such study.
Finally, from the clinical perspective, it is of highest importance
to subgroup and characterize cancers so as to identify
patients in need of aggressive therapy and those that could
probably be spared adjuvant systemic therapy and thereby the
adverse late health effects. We have been able to verify that
the intrinsic signature classifies tumors into five groups with
distinct tumor characteristics influencing relapse-free survival
and probably also predictive of therapy response.
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